Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-23T20:52:09.778Z Has data issue: false hasContentIssue false
  • English
  • Français

A Novel Approach to the Determination and Characterization of HIV Dementia

Published online by Cambridge University Press:  18 September 2015

P. Brouwers ,
E. Mohr ,
K. Hildebrand ,
M. Hendricks ,
J.J. Claus ,
I.S. Baron ,
M. Young  and
P. Pierce
P. Brouwers*
Affiliation:
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
E. Mohr
Affiliation:
University of Ottawa/Faculty of Medicine, Ottawa
K. Hildebrand
Affiliation:
University of Ottawa/Faculty of Medicine, Ottawa
M. Hendricks
Affiliation:
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
J.J. Claus
Affiliation:
National Instutute of Neurologic Disorders & Stroke, National Institutes of Health, Bethesda, Maryland
I.S. Baron
Affiliation:
Georgetown University Medical Center, Washington, DC
M. Young
Affiliation:
Georgetown University Medical Center, Washington, DC
P. Pierce
Affiliation:
Georgetown University Medical Center, Washington, DC
*
Pediatric Branch, National Cancer Institute, NIH Clinical Center, Bldg 10, Rm 13N240, Bethesda, Maryland 20892 U.S.A
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Neuropsychological studies of the pattern and extent of cognitive impairment in HIV-infected patients have mostly used deviations from control values and/or cut-off scores as criteria for classification of dementia. There is, however, no agreement as to how to define impairment, and classification is imprecise. Method: The current study used a dementia classification matrix, developed with a step-wise linear discriminant analysis of neuropsychological data from patients with primary neurodegenerative dementias, to classify symptomatic HIV patients as demented or non-demented, and further to differentiate cortical and subcortical dementia patterns. Thirty-two male and 2 female patients (mean age 39 ± 2) with symptomatic HIV disease (mean absolute CD4 count 195 ±41) participated in the study. Results: Thirty-five per cent of patients were classified as demented. Of these, 83% showed a subcortical pattern and 17% a cortical profile of deficits. Significant differences between patients classified as subcortically demented and those categorized as normal on neuropsychological measures associated with subcortical integrity further validated the classification. Measures of psychiatric status between subgroups were similar. Conclusion: Since certain treatments may delay or reverse cognitive deficits, the use of an objective classification method based on discriminant analysis may help to identify patients who may benefit from therapy.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 23 , Issue 2 , February 1996 , pp. 104 - 109
Copyright
Copyright © Canadian Neurological Sciences Federation 1996

References

1.Brouwers, P, Mohr, E, Hendricks, M, Baron, I.The use of discriminant analysis to differentiate the neuropsychological profile of HIV patients. J Clin Exp Neuropsychol 1989; 11: 35.Google Scholar
2.Navia, BA, Jordan, BD, Price, RW.The AIDS dementia complex: I. Clinical features. Ann Neurol 1986; 19: 517–524.CrossRefGoogle ScholarPubMed
3.Price, RW, Brew, B, Sidtis, J, et al. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988; 239: 586–592.CrossRefGoogle ScholarPubMed
4.Shaw, GM, Harper, ME, Hahn, BH, et al. HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science 1985; 227: 177–182.CrossRefGoogle ScholarPubMed
5.Koenig, S, Gendelman, HE, Orenstein, JM, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patient with encephalopathy. Science 1986; 233: 1089–1093.CrossRefGoogle ScholarPubMed
6.Resnick, L, DiMarzo-Veronese, F, Schupbach, J, et al. Intra-bloodbrain barrier synthesis of HTLV-III specific IgG in patients with neurological symptoms associated with AIDS or AIDS-related complex. N Engl J Med 1985; 313: 1498–1504.CrossRefGoogle ScholarPubMed
7.Hollander, H.Cerebrospinal fluid normalities and abnormalities in individuals infected with human immunodeficiency virus. J Infect Dis 1988; 158:855–858.CrossRefGoogle ScholarPubMed
8.McArthur, JC, Cohen, BA, Farzedegan, H, et al. Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatrie findings. Ann Neurol 1988; 23 (Suppl.): S34–S37.CrossRefGoogle Scholar
9.American Academy of Neurology (AAN) AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 infection. Neurology 1991; 41:778–785.CrossRefGoogle Scholar
10.Price, RW, Brew, BJ, Rosenblum, M.The AIDS dementia complex and HIV-1 brain infection: a pathogenetic model of virus-immune interaction. Res Publ Assoc Res Nerv Ment Dis 1990; 68: 269–290.Google ScholarPubMed
11.Brew, BJ, Currie, JN.HIV-related neurological disease. Med J Aust 1993; 158: 104–108.CrossRefGoogle ScholarPubMed
12.Janssen, RS, Nwanyanwu, OC, Selik, RM, Stehr-Green, JK.Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 1992; 42: 1472–1476.CrossRefGoogle ScholarPubMed
13.Grant, I, Atkinson, JH, Hesselink, JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med 1987; 107: 828–836.CrossRefGoogle ScholarPubMed
14.McArthur, JC, Cohen, BA, Seines, OA, et al. Low prevalence of neurological and neuropsychological abnormalities in otherwise healthy HIV-1-infected individuals: results from the Multicenter AIDS Cohort Study. Ann Neurol 1989; 26: 601–611.CrossRefGoogle ScholarPubMed
15.Seines, OA, Miller, E, McArthur, J, et al. HIV-1 infection: no evidence of cognitive decline during the asymptomatic stages. Neurology 1990; 40: 204–208.Google Scholar
16.Bornstein, RA, Pace, P, Rosenberger, P, et al. Depression and neuropsychological performance in asymptomatic HIV infection. Am J Psychiatry 1993; 150: 922–927.Google ScholarPubMed
17.Wilkie, FL, Eisdorfer, C, Morgan, R, Loewenstein, DA, Szapocznik, J.Cognition in early human immunodeficiency virus infection. Arch Neurol 1990; 47: 433–440.CrossRefGoogle ScholarPubMed
18.Lunn, S, Skydsbjerg, M, Schulsinger, H, et al. A preliminary report on the neuropsychologic sequelae of Human Immunodeficiency Virus. Arch Gen Psychiatry 1991; 48: 139–142.CrossRefGoogle ScholarPubMed
19.Adams, KM, Heaton, RK.Statement concerning the NIMH neuropsychological battery. J Clin Exp Neuropsychol 1990; 12: 960–962.CrossRefGoogle ScholarPubMed
20.Mohr, E, Brouwers, P, Claus, JJ, et al. Differential classification of dementia. Behavioural Neurology 1995; 8: 23–30.CrossRefGoogle ScholarPubMed
21.Cummings, JL.Subcortical Dementia, New York: Oxford University Press, 1990:Google Scholar
22.Tolosa, ES, Alvarez, R.Differential diagnosis of cortical vs. subcortical dementing disorders. Acta Neurol Scand 1992; 139: 47–53.CrossRefGoogle ScholarPubMed
23.Mayeux, R, Denaro, J, Hemenegildo, N, et al. A population-based investigation of Parkinson’s disease with and without dementia: relationship to age and gender. Arch Neurol 1992; 49: 492–497.CrossRefGoogle ScholarPubMed
24.Yarchoan, R, Berg, G, Brouwers, P, et al. Response of Human-Immuodeficiency-Virus-associated neurological disease to 3’-Azido-3’-Deoxythymidine. Lancet 1987; 1: 132–135.CrossRefGoogle Scholar
25.Schmitt, F, Bigley, J, McKinnis, R, et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988; 319: 1573–1578.CrossRefGoogle ScholarPubMed
26.Sidtis, JJ, Gatsonis, C, Price, RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neurol 1993; 33: 343–349.CrossRefGoogle ScholarPubMed
27.Wechsler, D.Wechsler Adult Intelligence Scale-Revised, New York: The Psychological Corporation, 1981.Google Scholar
28.Wechsler, D, Stone, CP.Wechsler Memory Scale, New York: The Psychological Corporation, 1945.Google Scholar
29.Osborne, D, Davis, LJ.Standard Scores for Wechsler Memory Scale Subtests. J Clin Psychol 1978; 34: 115–116.3.0.CO;2-J>CrossRefGoogle ScholarPubMed
30.Kirk, RE.Experimental design: procedures of the behavioral sciences, Belmont, CA: Brooks/Cole Publishing Co., 1968.Google Scholar
31.Raven, JC.Guide to Using the Coloured Progressive Matrices. London: H.K. Lewis, 1965.Google Scholar
32.Dunn, LM.Peabody Picture Vocabulary Test – Revised Manual, Circle Pines, MN: American Guidance Service, 1981.Google Scholar
33.Jastak, S, Wilkinson, G.The Wide Range Achievement Test-Revised: Administration Manual, Wilmington, DE: Jastak Associates, 1984.Google Scholar
34.Spreen, O, Benton, AL.Neurosensory Center Comprehensive Examination for Aphasia (NCCEA), Victoria: University of Victoria, Neuropsychology Laboratory, 1977.Google Scholar
35.Money, JA.Standardized Road Map of Direction Sense, San Rafael, CA. Academic Therapy Publications, 1976.Google Scholar
36.Lezak, MD.Neuropsychological Assessment, 2nd edition. New York: Oxford University Press, 1983.Google Scholar
37.Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J.An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571.CrossRefGoogle ScholarPubMed
38.Navia, BA.The AIDS dementia complex. In: Cummings, JL, ed. Subcortical Dementia, New York: Oxford University Press, 1990: 181–198.Google Scholar
39.Chui, HC.Dementia: a review emphasizing clinicopathologic correlation and brain – behavior relationships. Arch Neurol 1989; 46: 806–814.CrossRefGoogle ScholarPubMed
40.Navia, BA, Cho, ES, Petito, CK, Price, RW.The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986; 19: 525–535.CrossRefGoogle ScholarPubMed
41.Budka, H, Costanzi, G, Cristina, S, et al. Brain pathology induced by infection with the human immunodeficiency virus (HIV): a histological, immunocytochemical, and electron microscopical study of 100 autopsy cases. Acta Neuropathol 1987; 75: 185–198.CrossRefGoogle ScholarPubMed
42.Aylward, EH, Henderer, JD, McArthur, JC, et al. Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 1993; 43: 2099–2104.CrossRefGoogle ScholarPubMed
43.Rottenberg, DA, Moeller, JR, Strother, SC, et al. The metabolic pathology of the AIDS dementia complex. Ann Neurol 1987; 22: 700–706.CrossRefGoogle ScholarPubMed
44.Brunetti, A, Berg, G, Di Chiro G, et al. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3’-azido-2’, 3’-dideoxythymidine (AZT, zidovudine): a PET-FDG study. J Nucl Med 1989; 30: 581–590.Google ScholarPubMed
45.Brouwers, P, Cox, CS, Martin, A, Chase, TN, Fedio, P.Differential perceptual-spatial impairment in Huntington’s and Alzheimer’s dementias. Arch Neurol 1984; 41: 1073–1076.CrossRefGoogle ScholarPubMed
46.Mohr, E, Brouwers, P, Claus, JJ, et al. Visuospatial cognition in Huntington’s disease. Mov Disord 1991; 6: 127–132.CrossRefGoogle ScholarPubMed
47.Perdices, M, Cooper, DA.Simple and choice reaction time in patients with human immunodeficiency virus infection. Ann Neurol 1989; 25: 460–467.CrossRefGoogle ScholarPubMed
48.Miller, EN, Satz, P, Visscher, B.Computerized and conventional neuropsychological assessment of HIV-1 infected homosexual men. Neurology 1991; 41: 1608–1616.CrossRefGoogle ScholarPubMed
49.Wilkie, FL, Morgan, R, Fletcher, MA, et al. Cognitive and immune function in HIV-1 infection. AIDS 1992; 6: 977–981.CrossRefGoogle ScholarPubMed
50.Martin, A, Heyes, MP, Salazar, AM, et al. Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. Neuropsychiatr Clin Neurosci 1992; 4: 270–279.Google ScholarPubMed
51.Podraza, AM, Bornstein, RA, Whitacre, CC, et al. Neuropsychological performance and CD4 levels in HIV-1 asymptomatic infection. J Clin Exp Neuropsychol 1994; 16: 777–783.CrossRefGoogle ScholarPubMed
52.Grant, I, Atkinson, JH.Neurogenic and psychogenic behavioral correlates of HIV infection. Res Publ Assoc Res Nerv Ment Dis 1990; 68:291–304.Google ScholarPubMed
53.Hollander, H.Neurologic and psychiatric manifestations of HIV disease. J Gen Int Med 1991; 6 (Jan/Feb Suppl.): S24–S31.CrossRefGoogle ScholarPubMed
54.Rubinow, DR, Berrettini, CH, Brouwers, P, Lane, HC.Neuropsychiatrie consequences of AIDS. Ann Neurol 1988; 23 (Suppl.): S24–S26.CrossRefGoogle Scholar
55.Schmitt, FA, Dickson, LR, Brouwers, P.Neuropsychological response to anti-retroviral therapy in HIV infection. In: Grant, I, Martin, A, eds. Neuropsychology of HIV infection: current research and new directions, Oxford: Oxford University Press, 1994: 276–294.Google Scholar
56.Pizzo, PA, Eddy, J, Falloon, J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988; 319: 889–896.CrossRefGoogle ScholarPubMed
57.Yarchoan, R, Pluda, JM, Thomas, RV, et al. Long-term toxicity/activity profile of 2’, 3’-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990; 336: 526–529.CrossRefGoogle ScholarPubMed
58.Brouwers, P, Moss, H, Wolters, P, et al. Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immuno-deficiency virus infection. J Pediatr 1990; 117: 980–985.CrossRefGoogle Scholar
59.Balis, FM, Pizzo, PA, Butler, KM, et al. Clinical pharmacology of 2’, 3’-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992; 165: 99–104.CrossRefGoogle ScholarPubMed
60.Brouwers, P, DeCarli, C, Tudor-Williams, G, et al. Interrelations among patterns of change in neurocognitive, CT brain imaging, and CD4 measures associated with anti-retroviral therapy in children with symptomatic HIV infection. Adv Neuroimmunol 1994; 4:223–231.CrossRefGoogle ScholarPubMed